Skip to content

Assembly Biosciences ASMB Stock-Based Comp

Stock-Based Comp at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$16.67M+4.0%
ALN
Alnylam PharmaceuticalsALNY
$70.15M+23.7%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$3.58M+10.3%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$1.36M-61.9%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$12.09M-14.0%
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
$6.74M-35.2%

Other financials

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K
Free cash flow-$22.1M+5.6%

Valuation

See full
Market cap$480.77M+262%
Enterprise value$452.14M+302%
P/S6.8×+2.6×

Profitability

See full
Operating margin-116.8%-26.1pp
Net margin-103.6%-22.7pp
FCF margin-150%-231pp

Returns & leverage

See full
Return on equity-36.9%-15.1pp
Debt / equity-0.1×
Current ratio6.6×+4.6×

Where this comes from

Reported directly by Assembly Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Assembly Biosciences's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Assembly Biosciences's stock-based comp?
Assembly Biosciences (ASMB) reported stock-based comp of $1.12M in Q1 2026.
How has Assembly Biosciences's stock-based comp changed year-over-year?
Assembly Biosciences's stock-based comp increased by 56.7% year-over-year, from $712K to $1.12M.
What is the long-term trend for Assembly Biosciences's stock-based comp?
Over 4 years (2021 to 2025), Assembly Biosciences's stock-based comp has grown at a -2.8% compound annual growth rate (CAGR), from $5.24M to $4.68M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.